Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy By Ogkologos - February 19, 2026 81 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the marginal zone lymphoma cohort of the TRANSCEND FL study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian Patient Guide in Bladder Cancer Now Available Also in French Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma MOST POPULAR Preclinical Study May Have Found New Treatment Option for Triple-Negative Breast... June 8, 2021 NICE doesn’t recommend ibrutinib drug for those with Waldenstrom’s macroglobulinaemia May 23, 2022 What’s Your Mantra? July 28, 2021 Selpercatinib Slows Progression of RET-Positive Lung, Medullary Thyroid Cancers November 15, 2023 Load more HOT NEWS First Prospective Description of Familial EGFR-mutated Lung Cancer Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced... ESMO Sarcoma and Rare Cancers Congress 2024 No Survival Benefit from Adding Preoperative Chemoradiotherapy to Perioperative Chemotherapy in...
